Verification of the impact on sequential therapy Of romosozumab according to the administration period of teriparatide
Not Applicable
- Conditions
- osteoporosis
- Registration Number
- JPRN-UMIN000036854
- Lead Sponsor
- Shinshu University School of Medicine Dept. of Orthopaedic Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1:Patients who are allergic to romosozumab or teriparatide or eldecalcidol 2:Pregnant or breast-feeding patients 3:Patients considered to be at high risk of developing osteosarcoma 4:Patients with primary malignant or metastatic bone tumors 5:Patients with metabolic bone disease other than osteoporosis 6:Patients with unexplained high ALP 7:Others, patients judged by the research director as inappropriate 8:Hypocalcemia (serum corrected calcium level less than 8.0mg/dL) 9:Severe renal failure (less than eGFR15)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method